Symbols / SPRC
SPRC Chart
About
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.04M |
| Enterprise Value | — | Income | -6.48M | Sales | 1.31M |
| Book/sh | 15.81 | Cash/sh | — | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | 0.00 | Forward P/E | — | PEG | — |
| P/S | 2.32 | P/B | 0.04 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 350.73 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | -12.81% | ROIC | — | Gross Margin | 38.74% |
| Oper. Margin | -5.70% | Profit Margin | 0.00% | Shs Outstand | 5.09M |
| Shs Float | 413.19K | Short Float | 4.92% | Short Ratio | 0.08 |
| Short Interest | — | 52W High | 10.92 | 52W Low | 0.58 |
| Beta | 1.25 | Avg Volume | 2.14M | Volume | 52.69K |
| Target Price | — | Recom | None | Prev Close | $0.60 |
| Price | $0.60 | Change | -0.15% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.59
Latest analyst target
3. DCF / Fair value
$5260.95
Fallback: EPS × 15 (assumed fair P/E). No FCF data; use with …
Ratings
Current target
$0.59
Low
—
High
—
Mean
—
- SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Fri, 13 Feb 2026 22
- New GERD procedure tech puts SciSparc into a $2.5B device market - Stock Titan ue, 13 Jan 2026 08
- What’s the RSI of SPRC stock - Weekly Profit Analysis & Verified Technical Signals - mfd.ru Sat, 14 Feb 2026 11
- Why Is SciSparc Stock (SPRC) Up 130% Today? - TipRanks Wed, 17 Sep 2025 07
- SciSparc stock soars after launching quantum computing initiative - Investing.com hu, 25 Sep 2025 07
- Why SciSparc (SPRC) Stock Is Skyrocketing Today - Benzinga Wed, 17 Sep 2025 07
- Precision Trading with SPRC Inc (SPRC) Risk Zones - Stock Traders Daily Fri, 30 Jan 2026 15
- SciSparc Stocks Surge 50% In Pre-Market After N2OFF Approves MitoCareX Acquisition - Nasdaq ue, 30 Sep 2025 07
- SciSparc Ltd. Enters Definitive Agreement to Acquire Controlling Interest in Miza III Ventures Inc. Valued at Approximately US$11.6 Million | SPRC Stock News - Quiver Quantitative Wed, 15 Oct 2025 07
- SciSparc targets $2.5B GERD device market with new MUSE patents - Stock Titan Mon, 26 Jan 2026 08
- SciSparc stock surges after N2OFF shareholders approve MitoCareX acquisition - Investing.com ue, 30 Sep 2025 07
- SciSparc (Nasdaq: SPRC) NeuroThera signs term sheet for 55% quantum data stake - Stock Titan ue, 02 Dec 2025 08
- US$11.6M Pharma Assets: SciSparc to Transfer Portfolio; Expected to Hold 75–84% of Miza - Stock Titan Wed, 15 Oct 2025 07
- Cannabinoid-antibiotic combo boosts MRSA-fighting power in pre-clinical studies - Stock Titan Mon, 02 Feb 2026 08
- SciSparc (Nasdaq: SPRC) to acquire MUSE GERD device IP for 19.99% equity - Stock Titan Wed, 26 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -385.25 | 30.13K | 1.62M | 0.00 |
| TaxRateForCalcs | 0.00 | 0.23 | 0.23 | 0.00 |
| NormalizedEBITDA | -6.77M | -5.45M | -9.41M | -5.74M |
| TotalUnusualItems | -206.00K | 131.00K | 7.06M | -3.00K |
| TotalUnusualItemsExcludingGoodwill | -206.00K | 131.00K | 7.06M | -3.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -6.28M | -5.12M | -2.59M | -5.79M |
| ReconciledDepreciation | 482.00K | 538.00K | 187.00K | 33.00K |
| ReconciledCostOfRevenue | 800.00K | 683.00K | 322.00K | 0.00 |
| EBITDA | -6.97M | -5.31M | -2.35M | -5.74M |
| EBIT | -7.46M | -5.85M | -2.54M | -5.78M |
| NetInterestIncome | 391.00K | -9.00K | -1.24M | -18.00K |
| InterestExpense | 30.00K | 9.00K | 36.00K | 12.00K |
| InterestIncome | 421.00K | 0.00 | 0.00 | 0.00 |
| NormalizedIncome | -6.08M | -5.22M | -8.03M | -5.79M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -6.28M | -5.12M | -2.59M | -5.79M |
| TotalExpenses | 8.55M | 8.65M | 9.63M | 5.77M |
| TotalOperatingIncomeAsReported | -7.32M | -6.82M | -8.29M | -5.77M |
| DilutedAverageShares | 277.38K | 19.41K | 8.38K | 3.76K |
| BasicAverageShares | 277.38K | 19.41K | 8.38K | 3.76K |
| DilutedEPS | -22.65 | -263.84 | -309.38 | -1.55K |
| BasicEPS | -22.65 | -263.84 | -309.38 | -1.55K |
| DilutedNIAvailtoComStockholders | -6.28M | -5.12M | -2.59M | -5.79M |
| AverageDilutionEarnings | 0.00 | 0.00 | 0.00 | 0.00 |
| NetIncomeCommonStockholders | -6.28M | -5.12M | -2.59M | -5.79M |
| NetIncome | -6.28M | -5.12M | -2.59M | -5.79M |
| MinorityInterests | 1.19M | 761.00K | 0.00 | 0.00 |
| NetIncomeIncludingNoncontrollingInterests | -7.47M | -5.88M | -2.59M | -5.79M |
| NetIncomeDiscontinuousOperations | 0.00 | |||
| NetIncomeContinuousOperations | -7.47M | -5.88M | -2.59M | -5.79M |
| TaxProvision | -14.00K | 22.00K | 14.00K | 0.00 |
| PretaxIncome | -7.49M | -5.86M | -2.58M | -5.79M |
| OtherIncomeExpense | -635.00K | -79.00K | 6.95M | -3.00K |
| SpecialIncomeCharges | -74.00K | -1.04M | 0.00 | 0.00 |
| GainOnSaleOfPPE | 1.27M | 0.00 | 0.00 | |
| WriteOff | 0.00 | 0.00 | ||
| ImpairmentOfCapitalAssets | 1.34M | 1.04M | 0.00 | 0.00 |
| RestructuringAndMergernAcquisition | 907.00K | 0.00 | ||
| EarningsFromEquityInterest | -429.00K | -210.00K | -109.00K | 0.00 |
| GainOnSaleOfSecurity | -132.00K | 1.17M | 7.06M | -3.00K |
| NetNonOperatingInterestIncomeExpense | 391.00K | -9.00K | -1.24M | -18.00K |
| TotalOtherFinanceCost | -2.21M | 1.20M | 6.00K | |
| InterestExpenseNonOperating | 30.00K | 9.00K | 36.00K | 12.00K |
| InterestIncomeNonOperating | 421.00K | 0.00 | 0.00 | 0.00 |
| OperatingIncome | -7.24M | -5.77M | -8.29M | -5.77M |
| OperatingExpense | 7.75M | 7.97M | 9.31M | 5.77M |
| OtherOperatingExpenses | 128.00K | 110.00K | 80.00K | 135.00K |
| ResearchAndDevelopment | 1.81M | 1.73M | 2.96M | 2.00M |
| SellingGeneralAndAdministration | 5.80M | 6.13M | 6.27M | 3.64M |
| SellingAndMarketingExpense | 1.51M | 2.48M | 1.08M | 0.00 |
| GeneralAndAdministrativeExpense | 4.29M | 3.65M | 5.19M | 3.64M |
| OtherGandA | 3.36M | 3.17M | 4.12M | 3.37M |
| SalariesAndWages | 926.00K | 483.00K | 1.07M | 272.00K |
| GrossProfit | 506.00K | 2.20M | 1.02M | 0.00 |
| CostOfRevenue | 800.00K | 683.00K | 322.00K | 0.00 |
| TotalRevenue | 1.31M | 2.88M | 1.35M | 0.00 |
| OperatingRevenue | 1.31M | 2.88M | 1.35M | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 515.63K | 33.65K | 12.45K | 5.66K |
| ShareIssued | 515.63K | 33.65K | 12.45K | 5.66K |
| TotalDebt | 46.00K | 76.00K | 27.00K | 63.00K |
| TangibleBookValue | 6.67M | 4.42M | 1.73M | 8.14M |
| InvestedCapital | 8.15M | 7.61M | 6.45M | 8.14M |
| WorkingCapital | 6.10M | 4.87M | 354.00K | 8.07M |
| NetTangibleAssets | 6.67M | 4.42M | 1.73M | 8.14M |
| CapitalLeaseObligations | 46.00K | 76.00K | 27.00K | 63.00K |
| CommonStockEquity | 8.15M | 7.61M | 6.45M | 8.14M |
| TotalCapitalization | 8.15M | 7.61M | 6.45M | 8.14M |
| TotalEquityGrossMinorityInterest | 8.94M | 9.59M | 6.45M | 8.14M |
| MinorityInterest | 785.00K | 1.97M | 0.00 | |
| StockholdersEquity | 8.15M | 7.61M | 6.45M | 8.14M |
| OtherEquityInterest | 11.75M | 11.28M | 10.93M | 10.08M |
| GainsLossesNotAffectingRetainedEarnings | 497.00K | 497.00K | 497.00K | 497.00K |
| ForeignCurrencyTranslationAdjustments | 497.00K | 497.00K | 497.00K | 497.00K |
| RetainedEarnings | -74.97M | -68.69M | -63.57M | -60.98M |
| CapitalStock | 70.89M | 64.53M | 58.59M | 58.54M |
| CommonStock | 70.89M | 64.53M | 58.59M | 58.54M |
| TotalLiabilitiesNetMinorityInterest | 1.41M | 1.59M | 4.16M | 1.77M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 9.00K | 24.00K | 0.00 | 18.00K |
| LongTermDebtAndCapitalLeaseObligation | 9.00K | 24.00K | 0.00 | 18.00K |
| LongTermCapitalLeaseObligation | 9.00K | 24.00K | 0.00 | 18.00K |
| CurrentLiabilities | 1.40M | 1.57M | 4.16M | 1.76M |
| OtherCurrentLiabilities | 341.00K | 532.00K | 2.74M | 359.00K |
| CurrentDebtAndCapitalLeaseObligation | 37.00K | 52.00K | 27.00K | 45.00K |
| CurrentCapitalLeaseObligation | 37.00K | 52.00K | 27.00K | 45.00K |
| CurrentDebt | 441.00K | |||
| OtherCurrentBorrowings | 441.00K | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 130.00K | 104.00K | 77.00K | 38.00K |
| PayablesAndAccruedExpenses | 891.00K | 883.00K | 1.31M | 1.31M |
| CurrentAccruedExpenses | 75.00K | 48.00K | 1.00M | 45.00K |
| Payables | 816.00K | 835.00K | 312.00K | 1.27M |
| OtherPayable | 33.00K | 14.00K | 71.00K | |
| AccountsPayable | 816.00K | 802.00K | 298.00K | 1.20M |
| TotalAssets | 10.35M | 11.18M | 10.61M | 9.92M |
| TotalNonCurrentAssets | 2.84M | 4.74M | 6.09M | 92.00K |
| InvestmentsAndAdvances | 1.31M | 1.44M | 1.32M | 0.00 |
| InvestmentinFinancialAssets | 354.00K | 659.00K | 730.00K | 0.00 |
| LongTermEquityInvestment | 952.00K | 781.00K | 591.00K | 0.00 |
| InvestmentsinAssociatesatCost | 952.00K | 781.00K | 591.00K | 0.00 |
| GoodwillAndOtherIntangibleAssets | 1.48M | 3.19M | 4.72M | 0.00 |
| NetPPE | 59.00K | 108.00K | 57.00K | 92.00K |
| AccumulatedDepreciation | -40.00K | -117.00K | -65.00K | -22.00K |
| GrossPPE | 99.00K | 225.00K | 122.00K | 114.00K |
| Leases | 181.00K | 78.00K | 78.00K | |
| MachineryFurnitureEquipment | 24.00K | 44.00K | 44.00K | 36.00K |
| BuildingsAndImprovements | 75.00K | 181.00K | 78.00K | 78.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 7.50M | 6.45M | 4.51M | 9.82M |
| RestrictedCash | 20.00K | 65.00K | 60.00K | 45.00K |
| PrepaidAssets | 350.00K | 275.00K | 40.00K | 348.00K |
| Inventory | 113.00K | 742.00K | 668.00K | 0.00 |
| FinishedGoods | 113.00K | 742.00K | 668.00K | 0.00 |
| Receivables | 4.96M | 287.00K | 168.00K | 2.56M |
| OtherReceivables | 714.00K | 265.00K | 91.00K | 2.56M |
| DuefromRelatedPartiesCurrent | 15.00K | 0.00 | ||
| LoansReceivable | 4.22M | 0.00 | ||
| AccountsReceivable | 10.00K | 22.00K | 77.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 2.06M | 5.08M | 3.57M | 6.88M |
| OtherShortTermInvestments | 517.00K | 3.00M | 0.00 | |
| CashAndCashEquivalents | 1.54M | 2.08M | 3.57M | 6.88M |
| CashFinancial | 1.54M | 2.08M | 3.57M | 6.88M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -5.10M | -5.89M | -12.79M | -5.10M |
| RepaymentOfDebt | -54.00K | -47.00K | -70.00K | -207.00K |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 6.25M | 5.55M | 9.01M | 7.70M |
| CapitalExpenditure | -4.87M | -35.00K | ||
| EndCashPosition | 1.54M | 2.08M | 3.57M | 6.88M |
| BeginningCashPosition | 2.08M | 3.57M | 6.88M | 1.95M |
| EffectOfExchangeRateChanges | 0.00 | |||
| ChangesInCash | -536.00K | -1.50M | -3.30M | 4.93M |
| FinancingCashFlow | 6.19M | 8.48M | 11.70M | 10.06M |
| CashFlowFromContinuingFinancingActivities | 6.19M | 8.48M | 11.70M | 10.06M |
| NetOtherFinancingCharges | 2.98M | 3.00K | ||
| InterestPaidCFF | -8.00K | -7.00K | -8.00K | 0.00 |
| ProceedsFromStockOptionExercised | 0.00 | 0.00 | 2.77M | 2.57M |
| CashDividendsPaid | 0.00 | 0.00 | 0.00 | 0.00 |
| NetCommonStockIssuance | 6.25M | 5.55M | 9.01M | 7.70M |
| CommonStockIssuance | 6.25M | 5.55M | 9.01M | 7.70M |
| NetIssuancePaymentsOfDebt | -54.00K | -47.00K | -70.00K | -207.00K |
| NetShortTermDebtIssuance | 0.00 | 0.00 | -188.00K | |
| ShortTermDebtPayments | 0.00 | 0.00 | -188.00K | |
| ShortTermDebtIssuance | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | -54.00K | -47.00K | -70.00K | -19.00K |
| LongTermDebtPayments | -54.00K | -47.00K | -70.00K | -19.00K |
| InvestingCashFlow | -1.62M | -4.09M | -7.08M | -70.00K |
| CashFlowFromContinuingInvestingActivities | -1.62M | -4.09M | -7.08M | -70.00K |
| NetOtherInvestingChanges | -4.03M | -5.00K | -15.00K | -35.00K |
| NetInvestmentPurchaseAndSale | 3.00M | -3.69M | -1.50M | 0.00 |
| SaleOfInvestment | 3.00M | |||
| PurchaseOfInvestment | 0.00 | -3.69M | -1.50M | 0.00 |
| NetBusinessPurchaseAndSale | -600.00K | -400.00K | -700.00K | 0.00 |
| SaleOfBusiness | 2.98M | 0.00 | 0.00 | |
| PurchaseOfBusiness | -600.00K | -400.00K | -700.00K | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -4.86M | 0.00 |
| PurchaseOfIntangibles | 0.00 | 0.00 | -4.86M | 0.00 |
| NetPPEPurchaseAndSale | 8.00K | 0.00 | -8.00K | -35.00K |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | 0.00 | -8.00K | -35.00K | |
| OperatingCashFlow | -5.10M | -5.89M | -7.92M | -5.06M |
| CashFlowFromContinuingOperatingActivities | -5.10M | -5.89M | -7.92M | -5.06M |
| ChangeInWorkingCapital | 136.00K | -833.00K | -703.00K | 643.00K |
| ChangeInOtherWorkingCapital | -15.00K | |||
| ChangeInPayablesAndAccruedExpense | 45.00K | -405.00K | 39.00K | 473.00K |
| ChangeInPayable | 45.00K | -405.00K | 39.00K | 473.00K |
| ChangeInAccountPayable | 25.00K | -397.00K | 0.00 | 353.00K |
| ChangeInInventory | 629.00K | -74.00K | -668.00K | 0.00 |
| ChangeInReceivables | -523.00K | -354.00K | -74.00K | 170.00K |
| ChangesInAccountReceivables | 12.00K | 55.00K | -77.00K | 0.00 |
| OtherNonCashItems | -897.00K | -2.21M | -6.58M | 9.00K |
| StockBasedCompensation | 569.00K | 196.00K | 897.00K | 43.00K |
| AssetImpairmentCharge | 1.34M | 1.04M | 0.00 | 0.00 |
| DepreciationAmortizationDepletion | 482.00K | 538.00K | 187.00K | 33.00K |
| DepreciationAndAmortization | 482.00K | 538.00K | 187.00K | 33.00K |
| OperatingGainsLosses | 734.00K | 1.26M | 879.00K | |
| EarningsLossesFromEquityInvestments | 429.00K | 210.00K | 109.00K | 0.00 |
| GainLossOnInvestmentSecurities | 305.00K | 1.05M | 770.00K | |
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -7.47M | -5.88M | -2.59M | -5.79M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for SPRC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|